• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Creative Bio-Peptides Inc.

Creative Bio-Peptides Inc.

  • Home
  • Company
    • Our Company
    • Our People
  • Science
    • Introduction
    • RECEPTIDES
    • Publications
  • Therapy Areas
    • Persistent Post-Surgical Pain
    • Parkinson’s Disease
    • Opioid Use Disorders
  • News
  • Contact
  • LinkedIn

Persistent Post-Surgical Pain

More than 100 million people in the United States and Europe undergo surgical procedures each year.  It has been estimated that acute postoperative pain will develop into persistent postoperative surgical pain (PPSP) in as many as 20% to 50% of individuals after common operations (Richebe, 2018). Chronic pain is pain that lasts more than 3 months. Since chronic pain can be severe in up to 10% of these patients, PPSP represents a major clinical problem—affecting at least 450,000 people in the US each year.  Inflammation and nerve injury amplifies and maintains pain signaling. Persistent pain is frequently accompanied, indeed caused by chronic inflammation.  Our RAP’s (receptor active peptides) balances the inflammation that damages nerves and causes neuropathic, diabetic and other types of pain (Padi, 2012) to promote neuroregeneration and alleviate persistent pain..

Footer

Creative Bio-Peptides Inc.

Rockville, MD
USA  20854

  • LinkedIn

  • CCR5 Antagonist RAP-103 Protects Synapses in Dementia May 29, 2024
  • RAP-103 Inhibits Opioid-derived Dependence, Withdrawal and Respiratory Depression  Jul 19, 2022
  • RAP-103 Benefits in Pain Published Jul 14, 2022
  • BioHealth Innovation Press Release Features Creative Bio-Peptides Nov 30, 2021
  • A Conversation with CBO Michael Simon Apr 8, 2021
  • NIH SBIR AWARD FOR SYNAPSE PROTECTING TREATMENTS FOR ALZHEIMER’S DISEASE Sep 28, 2020
  • CREATIVE BIO-PEPTIDES RECEIVES NIH HEAL AWARD FOR OPIOID ABUSE DISORDERS Jan 20, 2020
  • CREATIVE BIO-PEPTIDES and LEIDOS AWARDED US DOD CONTRACT Jan 18, 2020

Read more news

Copyright © 2025 Creative Bio-Peptides Inc.